Altimmune, Inc. (ALT)
2.645
-0.08
(-3.11%)
USD |
NASDAQ |
Jun 09, 16:00
2.65
0.00 (0.00%)
After-Hours: 20:00
Altimmune Research and Development Expense (Quarterly) : 16.17M for March 31, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Agenus, Inc. | 11.82M |
| Amgen, Inc. | 1.719B |
| Halozyme Therapeutics, Inc. | 25.56M |
| Protalix Biotherapeutics, Inc. | 5.426M |
| Humacyte, Inc. | 19.46M |